ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print

SK Biopharm highlights drugs pipeline ahead of planned $800m IPO

South Korean drugmaker to start clinical test for anticancer treatment next year

If the float goes as planned, it would be the country's largest IPO since 2017.   © Reuters

SEOUL -- South Korean drugmaker SK Biopharmaceuticals started the run-in to its $800 million initial public offering by offering more details of its development pipeline, saying it would begin clinical trials of a cancer treatment next year.

The share offering by SK Biopharmaceutical is expected to be the biggest in South Korea for three years. It comes as the country's pharmaceutical industry has gained global attention thanks to South Korea's swift response to the coronavirus outbreak.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more